Patient with disseminated malignant tumor of the pancreas. Application of liposomal irinotecan as a new option of palliative treatment

• Autorzy: , , Rafał Becht
• Języki publikacji: EN

Abstrakty

EN

In palliative treatment of pancreatic neoplasms, chemotherapy regimens with gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, 5-fluorouracil or combinations of these drugs are used. The registration of liposomal irinotecan in the treatment of stage IV disease in patients with progression after gemcitabine creates new options for the treatment choice. The described case concerns a relatively young patient in whom the use of liposomal irinotecan in the registration indication turned out to be a safe and well-tolerated treatment.

Słowa kluczowe

EN

liposomal irinotecan; malignant neoplasm of the pancreas; pancreatic cancer

• Wydawca: Medical Education
• Czasopismo: OncoReview
• Rocznik: 2021
• Tom: 11
• Numer: 3
• Strony: 73-76

Twórcy

autor

,

• Clinical Department of Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian Medical University of Szczecin; Independent Public Clinic Hospital no. 1

autor

Rafał Becht

• Clinical Department of Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian Medical University of Szczecin; Independent Public Clinic Hospital no. 1

Bibliografia

• 1. Ducreux M, Cuhna A Sa, Caramella C et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 25(suppl 5): V56-V68.
• 2. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2019 r.
• 3. Wang-Gillam A, Hubner RA, Siveke JT et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019; 108: 78-87.

• Typ dokumentu: article